Dr. Jarecha’s expertise in managing the imaging components of more than 300 oncology, haemato-oncology, musculoskeletal, and advanced imaging clinical trials led to the submission and approval of more than 20 regional and global oncology-indication treatments.
Collaborated with thought leaders, Dr. Bruce Cheson for Lugano criteria, Dr. Joseph Mikhael, and Dr. Shaji Kumar for multiple myeloma criteria, in establishing standards that have been adopted as regulatory endpoints in clinical trials
Developed strategic partnerships with the leading pharma and biotech clients to support the imaging-based efficacy aspects of the programs of priority
Executed studies with fast turnaround to support the regulatory timelines. Successfully executed a study, which typically takes 6 months, in 6 weeks from the regulatory request to submission of the independent reads
Worked with the product management team to develop a hematology standard offering product to support the range of therapies under current investigation, including bi-specific antibodies and CAR-T therapies for indications like lymphoma, leukemia, and multiple myeloma
Held leadership positions in the Quantitative Imaging Biomarkers Alliance (QIBA) – CT Volumetry Biomarker Committee co-chair, CT Coordinating Committee co-chair, Steering and Executive Committee, served as an active member of PINTAD, and a contributing member of the ProLoG committee
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical) | Journal of Nuclear Medicine
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical) | Journal of Nuclear Medicine
Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion – Annals of Oncology
